Image Source : CNBC TV18
Aarti Drugs Ltd has reported a stable financial performance for the June quarter, reflecting resilience in its core pharmaceutical operations despite sectoral headwinds.
Key highlights:
-
Consolidated revenue from operations reached ₹5.91 billion, driven by consistent demand for active pharmaceutical ingredients (APIs) and specialty chemicals.
-
Net profit stood at ₹539.1 million, indicating healthy margins and operational discipline.
Performance insights:
-
The company continues to benefit from its diversified product portfolio across antidiabetic, antiinflammatory, and cardiovascular segments.
-
Export volumes remained steady, although pricing pressure in certain geographies impacted topline growth.
-
Operational efficiencies and cost control measures helped sustain profitability amid volatile input costs
Strategic outlook:
-
Aarti Drugs is investing in capacity expansion and backward integration to strengthen supply chain reliability.
-
Management remains optimistic about margin improvement in H2, supported by stabilizing raw material prices and new product launches.
Sources: Business Standard, CNBC TV18, MarketsMojo, Aarti Drugs Ltd Regulatory Filings
Advertisement
Advertisement